Health Care & Life Sciences » Pharmaceuticals | Concordia International Corp.

Concordia International Corp. | Income Statement

Fiscal year is January-December. All values CAD Millions.
2013
2014
2015
2016
2017
Sales/Revenue
42
135
504
1,081
813
Cost of Goods Sold (COGS) incl. D&A
9
32
175
509
543
Gross Income
33
103
330
572
269
SG&A Expense
11
49
108
237
168
EBIT
21
53
-
335
102
Unusual Expense
11
18
119
1,757
1,634
Non Operating Income/Expense
-
1
5
5
2
Interest Expense
7
13
164
397
658
Pretax Income
3
21
66
1,786
2,113
Income Tax
-
8
28
45
48
Consolidated Net Income
3
13
38
1,741
2,065
Net Income
3
13
38
1,741
2,065
Net Income After Extraordinaries
3
13
35
1,739
2,065
Net Income Available to Common
3
13
40
1,743
2,065
EPS (Basic)
0.39
0.47
1.11
34.17
40.37
Basic Shares Outstanding
6
26
36
51
51
EPS (Diluted)
0.39
0.47
1.08
33.65
40.36
Diluted Shares Outstanding
6
27
37
52
51
EBITDA
21
66
319
580
398
Other Operating Expense
1
-
-
-
-
Non-Operating Interest Income
-
-
-
29
80

About Concordia International

View Profile
Address
277 Lakeshore Road East
Oakville Ontario L6H 1J9
Canada
Employees -
Website http://www.concordiarx.com
Updated 09/14/2018
Concordia International Corp. is a pharmaceutical company, which engages in owning and licensing a diversified portfolio of branded and generic prescription products. It operates through the Concordia North America and Concordia International segments. The Concordia North America segment focuses primarily on the United States pharmaceutical market and offers products under the brand of Donnatal, Zonegran, Nilandron, Lanoxin, Plaquenil, and Photofrin.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.